{'fraction_non_alphanumeric': 0.0554932735426009, 'fraction_numerical': 0.06838565022421525, 'mean_word_length': 4.6847133757961785, 'pattern_counts': {'":': 0, '<': 4, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[THE ROLE OF GENETIC POLYMORPHISMS TOLL-LIKE RECEPTOR 4 AND 7 IN THE CHRONIC HEPATITIS C AND GENDER FEATURES OF THEIR DISTRIBUTION].

The aim of the study was to investigate the prevalence of polymorphisms Asp299Gly (rs4986790) TLR4 gene and Gln11Leu (rs179008) TLR7 gene in patients with chronic hepatitis C in general and in gender distribution. To achieve this goal the study using the methods of "case-control", which included 125 patients with chronic hepatitis C who were treated in the Poltava Regional Clinical Hospital of Infectious Diseases. The group of population control for the study of the prevalence of polymorphisms Asp299Gly TLR4 gene included 90 healthy residents of the Poltava region, for Gln11Leu gene TLR7 - 85. Gender groups were equivalent. The study found that in patients with chronic hepatitis C genotype Asp299Gly TLR4 gene was detected in 15.2%, allele 299Gly - in 7.6%, which is 4.5-4.6 times higher than their rate in control group (3.3% and 1.7%, respectively, p<0.01). The presence of polymorphism of the TLR4 gene in the genome can be considered as a predictor of development of chronic hepatitis C, factors of increased risk are the Asp299Gly genotype and the allele 299Gly (OR=5.19, p<0.01 and OR=4.85, p<0.05 respectively). Рolymorphic genotypes Gln11Leu and Leu11Leu of the TLR7 gene recorded in 18.4% of patients with chronic hepatitis C, among them Gln11Leu heterozygous genotype was detected in 16.8%, homozygous Leu11Leu - at 1.6%, with no statistical difference from the population control (25.9%, 22.4%, 3.5%, respectively, p>0.05). "Mutant" genotypes of the TLR7 gene were determined significantly more often in women with chronic hepatitis C (27.1%) and in healthy people (39.5%) comparing to men (13.0% and 14.9%, respectively, p<0.05).